Biotech catalyst, news and analysis PDUFA tracker
Viridian Therapeutics Inc
Biotech does not need to be vague to be speculative. The best watchlist stories usually sit in the middle: visible enough to be researched, near enough to matter, but still uncertain enough to create price discovery. MannKind ($MNKD), Viridian Therapeutics ($VRDN) and Vera Therapeutics ($VERA) fit that profile heading into late May, June and July 2026.
Why this follow-up exists
REVEAL-1 did not kill the TED thesis, but it changed the bar. The debate has moved from “does the drug work?” to “can Viridian still build a differentiated TED franchise that deserves premium valuation?”
Viridian’s REVEAL-1 press release was positive in the narrow, technical sense that matters most for binary biotech trading: the phase 3 trial hit its primary endpoint. Elegrobart, the company’s subcutaneous IGF-1R antibody for active thyroid eye disease, delivered a 54% proptosis responder rate in the every-four-week arm and 63% in the every-eight-week arm, versus 18% on placebo. The Q4W arm also showed strong diplopia data, including 51% complete resolution versus 16% on placebo. That is not failure language. That is a live asset with real activity. And yet the stock was hit as if something had gone badly wrong.
Viridian Therapeutics (VRDN) has started 2026 by reaffirming its "transformational" year narrative in the January 6 PR, which serves as a comprehensive roadmap update without any timeline shifts or negative surprises. This builds directly on the December 22, 2025 BLA acceptance for veligrotug (VRDN-001) in TED with Priority Review and PDUFA target of June 30, 2026 (as detailed in the previous report).
Viridian Therapeutics is trying to become the second major commercial player in thyroid eye disease after Amgen’s Tepezza, with a TED franchise built around veligrotug (IV) and VRDN-003 (subcutaneous), plus an FcRn platform (VRDN-006/008) that targets broader autoimmune indications.
Grafico è interessante, bel canale rialzista. Incamminata verso i suoi catalyst; non male se si riesce a prendere alla base del canale. Ha pochi volumi giornalieri il chè non mi piace tanto. Cmq interessante. Viridian Therapeutics (VRDN) — Merlintrader Report…
